LAG3 before you leap; plus BEE21, G20 highlights: a BioCentury podcast

Data from ASCO are positioning LAG3 to become the first new checkpoint to reach registration in more than six years. On the latest BioCentury This Week podcast, BioCentury’s editors explain why the T cell receptor is creating so much buzz leading into this year’s annual cancer conference. They also discuss highlights from the Bio€quity Europe 2021 meeting and assess how the world’s wealthiest nations are addressing the access gap for COVID-19 vaccines.

Senior Editor Lauren Martz zeroes in on expected data for compounds against LAG3 at the 2021 American Society of Clinical Oncology (ASCO) virtual conference that could lead to the first regulatory submission for a next-generation checkpoint blocker in years. ...